Evidence mapPaperPMID 40726320Full record

ArticleJournal of cachexia, sarcopenia and muscle2025

Circulating miR-144-3p as a Novel Independent Biomarker Associated With Low Muscle Strength Among Older Adults.

Hyung Eun Shin, Chang Won Won, Gustavo Duque, Miji Kim

Abstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Novel biomarkers for sarcopenia: a narrative review.Journal of orthopaedic surgery and research · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hyung Eun ShinDepartment of Health Sciences and Technology, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.
Chang Won WonElderly Frailty Research Center, Department of Family Medicine, College of Medicine, Kyung Hee University, Kyung Hee University Medical Center, Seoul, Republic of Korea.
Gustavo DuqueBone, Muscle & Geroscience Group, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Miji KimDepartment of Health Sciences and Technology, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.

Funding

Korea Health Technology R&D Project through the Korean Health Industry Development Institute (KHIDI) HI15C3153Korea National Institute of Health (KNIH) 2024-ER0603-01National Research Foundation of Korea (NRF) 2022R1A2C1012305National Research Foundation of Korea (NRF) RS-2023-00213338Patient-Centered Clinical Research Coordinating Center (PACEN) RS-2020-KH095863
6 · The paper itself

Abstract

backgroundLow muscle strength, a key component of sarcopenia, is significant in the development of adverse health outcomes among older adults. MicroRNAs (miRNAs) have been implicated in mechanisms of sarcopenia; however, their specific functions in sarcopenia components, particularly low muscle strength, remain unclear. We aimed to examine distinct miRNA signatures associated with muscle mass, strength, and performance and to explore independent biomarkers for identifying older adults with low muscle strength.

methodsNinety-six older adults were selected from the Korean Frailty and Aging Cohort Study using stratified random sampling based on age and sex, and classified into four groups according to Asian Working Group for Sarcopenia 2019 criteria: normal (n = 25), low muscle mass (Low MM)-only (n = 23), low muscle strength (Low MS)-only (n = 25) and low physical performance (Low PP)-only (n = 23). MiRNA profiles were generated through miRNA sequencing, and differentially expressed (DE) miRNAs among groups were identified using log2|Fold Change (FC)| ≥ 1 and a Benjamini-Hochberg (BH)-adjusted p < 0.05. Subsequently, candidate miRNAs were validated by quantitative real-time polymerase chain reaction. Differences in relative miRNA expression between groups were assessed using analysis of variance. The utility of identified miRNAs for discriminating older adults with low muscle strength was assessed using receiver operating characteristic (ROC) analysis.

resultsIn 96 older adults (50.0% women, mean age 76.6 ± 3.6 years), 16, 5 and 1 DE miRNAs were observed in comparisons of Low MS-only vs. Low MM-only, Low PP-only vs. Low MM-only, and Low PP-only vs. Low MS-only, respectively (log2|FC| ≥ 1 and BH-adjusted p < 0.05). Among these, miR-144-3p, miR-142-3p and miR-122-3p overlapped across at least two comparisons. In the validation phase, miR-144-3p exhibited significantly higher expression in the Low MS-only group than in other groups. Areas under the ROC curve (AUC) for miR-144-3p were 0.943 (95% CI = 0.854-1.000), 0.836 (95% CI = 0.698-0.974) and 0.844 (95% CI = 0.700-0.989) for distinguishing the Low MS-only group from normal, Low MM-only and Low PP-only groups, respectively (p < 0.001). Kyoto Encyclopedia of Genes and Genomes analysis revealed that identified novel miRNAs were mainly associated with FoxO and insulin signalling (BH-adjusted p < 0.001), with a trend toward neurotrophic signalling (BH-adjusted p = 0.0647).

conclusionsmiR-144-3p was identified as a novel biomarker for low muscle strength among older adults, independent of muscle mass and physical performance. Longitudinal studies are required to determine whether the identified miRNAs can function as predictive biomarkers for muscle strength decline.

Indexed as

BiomarkersCirculating MicroRNAMicroRNAsMuscle StrengthSarcopeniaAgedAged, 80 and overFemaleHumansMaleBiomarkersCirculating MicroRNAMicroRNAsMIRN144 microRNA, humancomponentsmiRNAsmuscle strengtholder adultsprofilingsarcopenia

Identifiers

PMID40726320
PMCPMC12304732

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.